In Reply: sentinel lymph node biopsy in melanoma
Leiter, Ulrike, and Garbe, Claus (2011) In Reply: sentinel lymph node biopsy in melanoma. Annals of Surgical Oncology, 18 (2). pp. 598-599.
PDF (Published Version)
- Published Version
Restricted to Repository staff only
[Extract] Di Georgi and colleagues propose that sentinel lymph node biopsy (SLNB) does not provide a real survival benefit and that the disease-free survival benefit is a result of lead-time bias. These are old arguments that have been repeatedly discussed in the literature. A reiterative statement of these arguments does not make them truer. The only new idea in the letter of Di Georgi and colleagues is to designate the gain of disease-free survival time as lead-time bias that shows that they did not really understand the concept of lead time bias.
|Item Type:||Article (Commentary)|
|Date Deposited:||28 Mar 2012 07:16|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111799 Public Health and Health Services not elsewhere classified @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920102 Cancer and Related Disorders @ 100%|
|Citation Count from Web of Science||